Literature DB >> 12910243

Isolation of drugs active against mammalian prions using a yeast-based screening assay.

Stéphane Bach1, Nicolas Talarek, Thibault Andrieu, Jean-Michel Vierfond, Yvette Mettey, Hervé Galons, Dominique Dormont, Laurent Meijer, Christophe Cullin, Marc Blondel.   

Abstract

We have developed a rapid, yeast-based, two-step assay to screen for antiprion drugs. The method allowed us to identify several compounds effective against budding yeast prions responsible for the [PSI+] and [URE3] phenotypes. These inhibitors include the kastellpaolitines, a new class of compounds, and two previously known molecules, phenanthridine and 6-aminophenanthridine. Two potent promoters of mammalian prion clearance in vitro, quinacrine and chlorpromazine, which share structural similarities with the kastellpaolitines, were also active in the assay. The compounds isolated here were also active in promoting mammalian prion clearance. These results validate the present method as an efficient high-throughput screening approach to identify new prion inhibitors and furthermore suggest that biochemical pathways controlling prion formation and/or maintenance are conserved from yeast to humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12910243     DOI: 10.1038/nbt855

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  60 in total

Review 1.  Emergence and natural selection of drug-resistant prions.

Authors:  James Shorter
Journal:  Mol Biosyst       Date:  2010-04-27

2.  Nanoliter microfluidic hybrid method for simultaneous screening and optimization validated with crystallization of membrane proteins.

Authors:  Liang Li; Debarshi Mustafi; Qiang Fu; Valentina Tereshko; Delai L Chen; Joshua D Tice; Rustem F Ismagilov
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-11       Impact factor: 11.205

Review 3.  Prions of fungi: inherited structures and biological roles.

Authors:  Reed B Wickner; Herman K Edskes; Frank Shewmaker; Toru Nakayashiki
Journal:  Nat Rev Microbiol       Date:  2007-08       Impact factor: 60.633

Review 4.  Antiprion drugs as chemical tools to uncover mechanisms of prion propagation.

Authors:  Déborah Tribouillard; Fabienne Gug; Hervé Galons; Stéphane Bach; Sven J Saupe; Marc Blondel
Journal:  Prion       Date:  2007-01-20       Impact factor: 3.931

Review 5.  Protein inheritance (prions) based on parallel in-register beta-sheet amyloid structures.

Authors:  Reed B Wickner; Frank Shewmaker; Dmitry Kryndushkin; Herman K Edskes
Journal:  Bioessays       Date:  2008-10       Impact factor: 4.345

6.  Prion 2016 Oral Abstracts.

Authors: 
Journal:  Prion       Date:  2016       Impact factor: 3.931

7.  The NatA acetyltransferase couples Sup35 prion complexes to the [PSI+] phenotype.

Authors:  John A Pezza; Sara X Langseth; Rochele Raupp Yamamoto; Stephen M Doris; Samuel P Ulin; Arthur R Salomon; Tricia R Serio
Journal:  Mol Biol Cell       Date:  2008-12-10       Impact factor: 4.138

8.  Progress and problems in the biology, diagnostics, and therapeutics of prion diseases.

Authors:  Adriano Aguzzi; Mathias Heikenwalder; Gino Miele
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition.

Authors:  Yanhong Pang; Sriram Kurella; Cécile Voisset; Dibyendu Samanta; Debapriya Banerjee; Ariane Schabe; Chanchal Das Gupta; Hervé Galons; Marc Blondel; Suparna Sanyal
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

10.  Inhibition of RNA recruitment and replication of an RNA virus by acridine derivatives with known anti-prion activities.

Authors:  Zsuzsanna Sasvari; Stéphane Bach; Marc Blondel; Peter D Nagy
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.